Healthcare Industry News: Naproxen
News Release - March 26, 2007
Victory Pharma, Inc. Sales Force Expansion Signifies Growth of Its US Commercial OperationsSAN DIEGO, March 26 (HSMN NewsFeed) -- Victory Pharma, Inc. a specialty pharmaceutical company with a portfolio of pain related products, today announced that it has completed its sales force expansion. The sales force promotes the Company's unique and innovative line of prescription pain products including recently acquired marketing rights for NAPRELAN®.
"This build out of our sales force denotes a significant milestone achievement for a fully functional commercial presence in North America," said Matt Heck, President of Victory. "We have been able to attract significant expertise in the ranks of our sales and sales management team," says Mike Goolsby, VP of Sales. Mr. Goolsby also states, "Due to the expansion we have already seen improvement in the sales trends of NAPRELAN® which began with the first sales team roll out in 2006."
Victory promotes NAPRELAN® (Naproxen sodium), a patented once-a-day formulation of Naproxen sodium and is currently the only once-a-day formulation of this particular non-steroidal anti-inflammatory (NSAID) agent. This NSAID has a well defined safety profile and is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendonitis, bursitis, acute gout, primary dysmenorrhea, and mild to moderate pain. The company believes NAPRELAN® can significantly improve dosing compliance for patients with pain.
"We are actively seeking to extend the reach of NAPRELAN® prescribing through co-promotion to additional specialties where we feel we can find quality partners," states Matt Heck, President of Victory Pharma, Inc.
About Victory Pharma, Inc.
Victory Pharma, Inc. is a private San Diego based specialty pharmaceutical company focused on acquiring, marketing and developing proprietary late stage pain and related products. Victory markets its existing pain products through its field sales force headquartered in Cary, NC. The Company is developing several products in pain and pain complementary markets including MGX-001, for treatment of chronic severe pain and a commonly associated opiate-induced side effect. MGX-001 is currently in Phase II clinical testing in the United States. Further information regarding Victory is available at http://www.VictoryPharma.com.
Naprelan® is a registered trademark of Elan Corporation, plc.
Source: Victory Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.